百明信康生物技术

Baiming Xinkang is a clinical-stage biotechnology company specializing in the development of innovative therapies for allergic and autoimmune diseases. The company leverages its proprietary recombinant allergen platform to create precise allergen-specific immunotherapies (AIT) that aim to provide long-term desensitization and disease modification. Its lead candidate, BM-101, is a recombinant birch pollen allergen currently in clinical development for allergic rhinitis. Baiming Xinkang operates with a global R&D strategy, maintaining facilities in China and Switzerland to bridge international scientific expertise. The company is backed by prominent venture capital firms and focuses on addressing significant unmet needs in the global allergy market. By utilizing standardized recombinant proteins, the company seeks to overcome the limitations of traditional allergen extracts, such as variability and safety concerns.